Loading…
Dianthus Therapeutics, Inc. is projected to rise to $131.04 by 2027, a +34% move from its current price of $97.60. DNTH is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $94.73 | $97.64 | $100.65 | +0.05% |
| Jul 14 | $93.59 | $97.69 | $101.97 | +0.09% |
| Jul 15 | $92.73 | $97.73 | $103.00 | +0.14% |
| Jul 16 | $92.03 | $97.78 | $103.89 | +0.18% |
| Jul 17 | $91.41 | $97.82 | $104.68 | +0.23% |
| Jul 18 | $90.86 | $97.87 | $105.41 | +0.27% |
| Jul 19 | $90.37 | $97.91 | $106.09 | +0.32% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $90.37 | $97.91 | $106.09 | +0.32% |
| Week 2 | $87.69 | $98.22 | $110.02 | +0.64% |
| Week 3 | $85.76 | $98.54 | $113.22 | +0.96% |
| Week 4 | $84.20 | $98.85 | $116.04 | +1.28% |
| Week 5 | $82.89 | $99.16 | $118.64 | +1.60% |
| Week 6 | $81.74 | $99.48 | $121.07 | +1.93% |
| Week 7 | $80.72 | $99.80 | $123.38 | +2.25% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company that engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, is a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212 is a bifunctional fusion protein that targets plasmacytoid dendritic cell BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.
Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Dianthus Therapeutics, Inc. (DNTH) is currently priced at $95.35 and trades with a market capitalization of $5.21B, holding a rank of 1340. The stock’s current price aligns with its 2026 forecast average of $95.35, and the broader price outlook projects a rising trajectory toward higher targets in subsequent years.
By 2030 the forecast average is $257.54, and by 2050 the forecast average is $2,046.49, indicating a long-run bullish path.
A major floor 43.2% below — a decisive break under it would weaken the trend.
The nearest floor, 21.7% below — buyers have tended to step in here.
Price is pressing into resistance (2.5% away) — a breakout level to watch.
A major ceiling 17.8% above — clearing it would confirm fresh momentum.
Key DNTH support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of DNTH market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $96.96 | Buy | $97.18 | Buy |
| MA 10 | $95.79 | Buy | $95.18 | Buy |
| MA 20 | $89.97 | Buy | $92.13 | Buy |
| MA 50 | $87.70 | Buy | $87.78 | Buy |
| MA 100 | $82.14 | Buy | $80.10 | Buy |
| MA 200 | $61.62 | Buy | $66.34 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 60.11 | Neutral |
| Stoch RSI (14) | 49.06 | Neutral |
| CCI (20) | 83.96 | Neutral |
| Williams %R (14) | -19.19 | Info |
| MACD (12,26,9) | 0.90 | Buy |
| ROC (12) | 11.50 | Buy |
| Bollinger %B (20,2) | 0.77 | Neutral |
| Stochastic %K (14) | 80.81 | Sell |
| TRIX (15) | 0.40 | Buy |
| Awesome (5,34) | 8.85 | Buy |
| Ultimate (7,14,28) | 56.47 | Neutral |
| Momentum (10) | 6.03 | Buy |
| Aroon Osc (25) | 76.00 | Buy |
| Hull MA (9) | 99.36 | Sell |
| ADX (14) | 17.62 | Neutral |
| ATR (14) | 2.57 | Info |
The 30-day technical picture is bullish with RSI14 at 60. The 50-day simple moving average is $86.61 and the 200-day simple moving average is $58.71. Key support is at $76.42 and resistance at $93.01, outlining a near-term trading range. The 30-day trading range is $77.14 to $117.86.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $36.20 | $97.60 | $138.78 | 0% | Neutral | |
| $103.26 | $131.04 | $176.57 | +34% | Bullish | |
| $145.31 | $190.27 | $266.95 | +95% | Bullish | |
| $171.48 | $230.47 | $333.69 | +136% | Bullish | |
| $190.20 | $261.59 | $388.90 | +168% | Bullish | |
| $222.98 | $313.20 | $476.49 | +221% | Bullish | |
| $232.73 | $333.40 | $517.77 | +242% | Bullish | |
| $247.67 | $361.42 | $571.87 | +270% | Bullish | |
| $283.97 | $421.76 | $678.86 | +332% | Bullish | |
| $351.94 | $531.62 | $869.40 | +445% | Bullish | |
| $491.41 | $801.78 | $1,401.23 | +722% | Bullish | |
| $1,136.07 | $2,120.74 | $4,080.56 | +20.7x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $36.20 | $97.60 | $119.68 | +0.00% |
| August 2026 | $87.41 | $103.47 | $125.98 | +6.01% |
| September 2026 | $85.27 | $101.73 | $125.39 | -1.68% |
| October 2026 | $84.33 | $101.28 | $126.14 | -0.44% |
| November 2026 | $88.00 | $106.29 | $133.53 | +4.95% |
| December 2026 | $90.26 | $109.61 | $138.78 | +3.12% |
Click any year to see its month-by-month DNTH forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Dianthus Therapeutics, Inc.'s 2026 outlook centres on $97.60, within a $36.20 to $138.78 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, DNTH could reach as high as $176.57, with a base case around $131.04 and support toward $103.26 — roughly +34% from $97.60. Momentum favours further upside here.
Expect DNTH to range from $145.31 to $266.95 through 2028. The $190.27 average target implies a +95% move from current prices. That is up +45% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The DNTH price prediction for 2029 points to an average of $230.47 (low $171.48, high $333.69) — a potential gain of +136% on today's $97.60. Momentum favours further upside here.
In 2030, DNTH is projected to trade between $190.20 and $388.90, averaging $261.59 — a potential gain of +168% from today's $97.60. That is up +14% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Dianthus Therapeutics, Inc.'s 2031 outlook centres on $313.20, within a $222.98 to $476.49 range. That is up +20% on the projected 2030 average. That marks a +221% change versus current levels. Momentum favours further upside here.
By 2032, DNTH could reach as high as $517.77, with a base case around $333.40 and support toward $232.73 — roughly +242% from $97.60. Buyers look set to stay in control over this stretch.
Expect DNTH to range from $247.67 to $571.87 through 2033. The $361.42 average target implies a +270% move from current prices. That is up +8% on the projected 2032 average. Momentum favours further upside here.
The DNTH price prediction for 2034 points to an average of $421.76 (low $283.97, high $678.86) — a potential gain of +332% on today's $97.60. Buyers look set to stay in control over this stretch.
In 2035, DNTH is projected to trade between $351.94 and $869.40, averaging $531.62 — a potential gain of +445% from today's $97.60. That is up +26% on the projected 2034 average. Momentum favours further upside here.
Dianthus Therapeutics, Inc.'s 2040 outlook centres on $801.78, within a $491.41 to $1,401.23 range. That is up +51% on the projected 2035 average. That marks a +722% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, DNTH could reach as high as $4,080.56, with a base case around $2,120.74 and support toward $1,136.07 — roughly +20.7x from $97.60. Momentum favours further upside here.
Investing $1,000 in DNTH today (≈ 10.245902 DNTH) could be worth
$21,728.86
+$20,728.86 (+2073%) by 2050 · US Dollar
Based on the average projected DNTH price of $2,120.74 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in DNTHwould be worth at today's price.
$1,000 invested in DNTH on Jul 10, 2025 (≈ 48.520134 DNTH) would be worth
$4,735.57
+$3,735.57 (+373.6%) today · 4.74× · US Dollar
Based on a DNTH entry price of $20.61 vs. today's $97.6.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $94.34 | $1,034.56 | +3.5% |
| 1 month ago | $76.42 | $1,277.15 | +27.7% |
| 3 months ago | $89.77 | $1,087.22 | +8.7% |
| 6 months ago | $39.12 | $2,494.89 | +149.5% |
| 1 year ago | $20.61 | $4,735.57 | +373.6% |
| All time (5.0y) ago | $144 | $677.78 | -32.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our DNTH forecast.
Our base-case forecast reaches $200.00 around 2029.
Implied market cap at $200.00: $10.93B
The multi-year forecast shows a pronounced growth path. The 2026 forecast average is $95.35 with a neutral sentiment for that year. By 2027 the average is $130.76 and the sentiment is bullish, rising to $192.81 in 2028 and $225.17 in 2029, with 2030 average at $257.54 and a bullish outlook.
The forecast envisions continued strength into 2040 with an average of $781.47 and a 2040 ROI of 719.6, and into 2050 with an average of $2,046.49 and an ROI of 2046.3, both marked bullish. The sentiment remains bullish across 2027–2050, underscoring a long-term uptrend potential, while noting that these figures are estimates, not guarantees, and subject to market and investment risks.
Tap a question to reveal the answer.
The 2030 forecast shows min $184.83, avg $257.54, max $388.39, roiPct 170.1, sentiment BULLISH.
The forecast points to a bullish path from 2027 onward, with 2027 avg $130.76, 2028 avg $192.81, 2029 avg $225.17, and 2030 avg $257.54, alongside rising ROI values (e.g., 37.1 in 2027, 102.2 in 2028, 136.2 in 2029, 170.1 in 2030). These are estimates and not guarantees.
Yes, the 2040 forecast shows an average of $781.47 and a max of $1,394.32, indicating the possibility of reaching a price near or above $1,000 within the forecast period.
Current price is $95.35 and market cap is $5.21B, with a rank of 1340.
RSI14 is 60, SMA50 is $86.61, SMA200 is $58.71, with a support of $76.42 and resistance of $93.01. The 30-day range runs from $77.14 to $117.86.
Dianthus Therapeutics, Inc. Community Discussion
0Share your Dianthus Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.